Characteristics of study participants
Patient ID . | Age, y . | Sex . | Genotype . | ALT/AST . | Viral load, × 105* . | Histology . | Date of Dx or prior Tx . |
|---|---|---|---|---|---|---|---|
| Chronic† | |||||||
| 3 | 52 | M | 1a | 41/42 | 189.0 | Fibrosis: stage 2 | Dx in 2/99; Peg-ribavirin/IFN |
| 33 | 52 | F | 1a | NA | 4.6 | Fibrosis: grade 2, stage 2 | Unknown |
| 51 | 47 | M | 1a | 76/48 | 6.9 | Fibrosis: grade 2, stage 2 | Dx in '96; Tx naive |
| 104 | 53 | M | 1b | 45/41 | 14.8 | Fibrosis: grade 2, stage 2 | Dx in '65; Peg-ribavirin × 3/IL-10 |
| 126 | 48 | M | 2a | 59/31 | NA§ | No biopsy taken | Tx naive |
| 351 | 61 | F | 1b | 80/96 | 5.2 | Fibrosis: grade 2, stage 3 | Tx naive |
| 402 | 20 | M | NA | 41/31 | 1.3 | No biopsy taken | Dx '01; Tx naive |
| 689 | 69 | M | 1a | 88/55 | 47.1 | Fibrosis: grade 2, stage 2-3 | Peg-ribavirin/IFN |
| 794 | 49 | F | NA | 35/70 | 0.5 | Cirrhosis: grade 3, stage 4 | Dx in '78; Tx naive |
| 804 | 22 | M | 1b | 188/113 | 11.6 | Advanced fibrosis, transition to cirrhosis: grade 2, stage 4 | Dx in 3/02; Tx naive |
| 812 | 65 | F | 1 | 51/42 | 16.2 | Fibrosis: stage 1 | Dx in '60s; Peg-ribavirin/IFN |
| 815 | 68 | M | NA | 247/112 | 4.5 | No biopsy taken | Dx in 9/01; Tx naive |
| 936 | 42 | F | 1a | 19/14 | 9.6 | Fibrosis | Dx in '95; Tx naive |
| Sustained responder‡ | |||||||
| 237 | 52 | M | 1a | 14/17 | <600 IU/mL | Cirrhosis: stage 4, grade 4 | Dx '00; Peg-ribavirin/IFN |
| 813 | 42 | F | 4a | 5/9 | <5 IU/mL∥ | No biopsy taken | Dx in '97; Peg-ribavirin/IFN |
| 976 | 41 | M | NA | 131/25 | <600 IU/mL | No biopsy taken | Dx '79; Peg-ribavirin/IFN |
Patient ID . | Age, y . | Sex . | Genotype . | ALT/AST . | Viral load, × 105* . | Histology . | Date of Dx or prior Tx . |
|---|---|---|---|---|---|---|---|
| Chronic† | |||||||
| 3 | 52 | M | 1a | 41/42 | 189.0 | Fibrosis: stage 2 | Dx in 2/99; Peg-ribavirin/IFN |
| 33 | 52 | F | 1a | NA | 4.6 | Fibrosis: grade 2, stage 2 | Unknown |
| 51 | 47 | M | 1a | 76/48 | 6.9 | Fibrosis: grade 2, stage 2 | Dx in '96; Tx naive |
| 104 | 53 | M | 1b | 45/41 | 14.8 | Fibrosis: grade 2, stage 2 | Dx in '65; Peg-ribavirin × 3/IL-10 |
| 126 | 48 | M | 2a | 59/31 | NA§ | No biopsy taken | Tx naive |
| 351 | 61 | F | 1b | 80/96 | 5.2 | Fibrosis: grade 2, stage 3 | Tx naive |
| 402 | 20 | M | NA | 41/31 | 1.3 | No biopsy taken | Dx '01; Tx naive |
| 689 | 69 | M | 1a | 88/55 | 47.1 | Fibrosis: grade 2, stage 2-3 | Peg-ribavirin/IFN |
| 794 | 49 | F | NA | 35/70 | 0.5 | Cirrhosis: grade 3, stage 4 | Dx in '78; Tx naive |
| 804 | 22 | M | 1b | 188/113 | 11.6 | Advanced fibrosis, transition to cirrhosis: grade 2, stage 4 | Dx in 3/02; Tx naive |
| 812 | 65 | F | 1 | 51/42 | 16.2 | Fibrosis: stage 1 | Dx in '60s; Peg-ribavirin/IFN |
| 815 | 68 | M | NA | 247/112 | 4.5 | No biopsy taken | Dx in 9/01; Tx naive |
| 936 | 42 | F | 1a | 19/14 | 9.6 | Fibrosis | Dx in '95; Tx naive |
| Sustained responder‡ | |||||||
| 237 | 52 | M | 1a | 14/17 | <600 IU/mL | Cirrhosis: stage 4, grade 4 | Dx '00; Peg-ribavirin/IFN |
| 813 | 42 | F | 4a | 5/9 | <5 IU/mL∥ | No biopsy taken | Dx in '97; Peg-ribavirin/IFN |
| 976 | 41 | M | NA | 131/25 | <600 IU/mL | No biopsy taken | Dx '79; Peg-ribavirin/IFN |
ALT indicates alanine aminotransferase; AST, aspartate aminotransferase; Dx, diagnosis; Peg, polyethylene glycol; IFN, interferon; NA, not available; Tx, treatment.
Viral load defined by quantitative polymerase chain reaction (PCR) at time of blood draw (Amplicor; Roche Molecular Diagnostics, Pleasanton, CA).
Chronic patient defined as a patient with HCV viral load and sustained liver injury for longer than 6 months as monitored by ALT/AST and/or liver biopsy.
Sustained responder defined as an individual who shows evidence of a past HCV infection but has maintained low viral load longer than 6 months after termination of therapy.
Prior data for patient 126 confirmed status as chronically infected.
Determined by Heptimax (Quest Diagnostics, Teterboro, NJ).